{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glaucoma/goals-outcome-measures/nice-quality-standards/","result":{"pageContext":{"chapter":{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards","depth":2,"htmlHeader":"<!-- begin field 73f91bcb-1a53-411a-a12f-756da571f0fc --><h2>NICE quality standards</h2><!-- end field 73f91bcb-1a53-411a-a12f-756da571f0fc -->","summary":null,"htmlStringContent":"<!-- begin item 89f30c90-ef7e-438d-b5e9-c30305c76570 --><!-- begin field cca329f8-32e1-4a40-82de-accd197bbf46 --><p><strong>In 2019 the NICE quality standard for glaucoma in adults (QS7) was updated and replaced by a quality standard on serious eye disorders. Statements relevant to the management of people with glaucoma include:</strong></p><ul><li><p>Statement 1: Adults with signs of possible glaucoma or related conditions on a routine sight test have additional tests before they are referred for a diagnosis.</p></li><li><p>Statement 5: Adults with chronic open angle glaucoma or related conditions have reassessment at specific intervals.</p></li><li><p>Statement 6: Adults with serious eye disorders are given a certificate of vision impairment as soon as they are eligible.</p></li></ul><p><strong>NICE also advises that 'Statements from the quality standard for glaucoma in adults that are still supported by the evidence may still be useful at a local level'. These include:</strong></p><ul><li><p>People are referred to a consultant ophthalmologist for further assessment and definitive diagnosis if the optometrist or other healthcare professional suspects chronic open angle glaucoma (COAG). There are local agreements in place for referral refinement.</p></li><li><p>People with elevated intraocular pressure alone are referred to an appropriately qualified healthcare professional for further assessment on the basis of perceived risk of progression to COAG. There are agreements in place for repeat measures.</p></li><li><p>People with COAG, suspected COAG, or with ocular hypertension (OHT) are diagnosed and have a management plan formulated by a suitably trained healthcare professional with competencies and experience in accordance with NICE guidance.</p></li><li><p>People with COAG, suspected COAG, or with OHT have a regular review of management options with their healthcare professional, taking into account comorbidity and other changed circumstances, including a discussion of the benefits and risks of stopping treatment for those at low risk of progressing to visual impairment.</p></li><li><p>Healthcare professionals involved in the care of a person with COAG, suspected COAG, or with OHT have appropriate documentation and records available at each clinical encounter in accordance with NICE guidance.</p></li><li><p>People with COAG who are progressing to loss of vision despite treatment or who present with advanced visual loss are offered surgery with pharmacological augmentation (MMC) as indicated and information on the risks and benefits associated with surgery.</p></li><li><p>People with COAG, suspected COAG, or with OHT are given the opportunity to discuss their diagnosis, prognosis, and management, and are provided with relevant and accessible information and advice at initial and subsequent visits in accordance with NICE guidance.</p></li><li><p>People with suspected COAG or with OHT who are not recommended for treatment are discharged from formal monitoring with a patient-held management plan and their discharge summary is sent to their GP and primary eye care professional.</p></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">NICE, 2019a</a>]</p><!-- end field cca329f8-32e1-4a40-82de-accd197bbf46 --><!-- end item 89f30c90-ef7e-438d-b5e9-c30305c76570 -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","lastRevised":"Last revised in November 2020","chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","fullItemName":"Management","slug":"management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}